Breaking News
Sort by:
Top Post
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen, a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, and […]
Holmusk Announces Closing of Strategic Investment from Healthcare and Life Science Industry Leaders
Holmusk, a leading global data science and digital health company building the world’s largest Real-World […]
PDC*line Pharma Raises €17.5 Million ($20.3M) in Series B2 Financing Round
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable […]
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]
Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing
Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery […]
EverImmune Raises €5M to Enter Clinical Phase in Microbiota Immuno-oncology
EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field […]
Northwest Biotherapeutics Announces $15 Million Financing
Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor […]
NovAliX Signs Partnership Agreement to Design and Screen Sanofi’s New DNA-Encoded Libraries
NovAliX, a Contract Research Organization (CRO) specializing in drug research and development, today announces its […]
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has entered into a definitive agreement […]
Novarad Partners with CureMetrix to Advance AI-Driven Mammography
Novarad, a leader in the development of medical imaging software, today announced a partnership with […]
Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more